In vivo studies of the BCLX inhibitor, A-1331852, already showed an enhancement of the effectiveness of paclitaxel [57], and new PROTAC-based concepts may facilitate clinical application avoiding thrombocytopenia [58, 59]. Here, BCL2L1 is linked to Thrombocytopenia.